![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION WHO RECEIVE OPIOID AGONIST THERAPY: TREATMENT UTILIZATION AND THE IMPACT OF CONCOMITANT PSYCHIATRIC MEDICATIONS
|
|
|
Reported by Jules Levin
EASL 2019 April 10-14 Vienna
JR Kramer1,2, A Puenpatom3, Y Cao1, H El-Serag1,2, F Kanwal1,2
1Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX, USA
2Department of Medicine, Baylor College of Medicine, Houston, TX, USA
3Merck & Co., Inc., Kenilworth, NJ, USA
![0416191](../images/041719/041619-2/0416191.gif)
![0416192](../images/041719/041619-2/0416192.gif)
![0416193](../images/041719/041619-2/0416193.gif)
![0416194](../images/041719/041619-2/0416194.gif)
![0416195](../images/041719/041619-2/0416195.gif)
![0416196](../images/041719/041619-2/0416196.gif)
![0416197](../images/041719/041619-2/0416197.gif)
![0416198](../images/041719/041619-2/0416198.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|